Metro International Biotech is developing an extensive portfolio of small-molecule NAD+ precursors that have been shown to increase cellular and mitochondrial NAD+ levels in vivo.
Metro International Biotech is initially targeting rare mitochondrial diseases, though modulating NAD+ has exhibited broad potential to treat a range of serious conditions and diseases.
A BROAD PIPELINE, INITIALLY TARGETING RARE MITOCHONDRIAL DISEASES
MIB-626 is a proprietary, crystallized precursor of NAD+ optimized for potency, bio distribution, pharmacodynamic and pharmacokinetic properties.
Metro International Biotech has conducted multiple IRB-approved human safety and bioavailability trials at a prominent Boston hospital, which demonstrated MIB-626 is well tolerated in healthy human volunteer subjects and raises blood levels of NAD+ and related metabolites.
friedreich’s ataxia (FA)
FA is an autosomal recessive inherited mitochondrial disease caused by mutation in the frataxin-encoding gene, which results in loss of coordination, fatigue, muscle loss, vision impairment, hearing loss, slurred speech, cardiomyopathy, diabetes and substantially reduced life expectancy. 1 in 50,000 people are affected and there are currently no disease-modifying therapies available.
Metro International Biotech intends to file an IND in mid-2019 for Phase 2 trials in Frederich’s Ataxia.
Mitochondrial myopathy is a set of mitochondrial diseases that cause progressive muscle weakness and exercise intolerance, due to electron transport chain defects in muscle fibers. Frequently, this manifests as progressive external ophthalmoplegia (PEO), a weakening of the muscles controlling eye movements, which has been slowed by NAD+ repletion in mouse models.
Metro International Biotech intends to file an IND in mid-2019 for Phase 2 trials in mitochondrial myopathy.
Through screening studies and determination of pharmacodynamic profiles, Metro International Biotech has developed a library of compounds, identifying analogs of MIB-626 with enhanced specificity and activity in various tissue types and specific organs.
Metro International Biotech intends to develop several of these compounds for specialized clinical indications, including for more mainstream diseases.